Aimmune Therapeutics saw its shares flying on Monday after the company gained Food and Drug Administration (FDA) approval for a first-of-its-kind peanut allergy treatment. In premarket trading on the stock market today, AIMT shares soared 9.2%, nearing 33.90. The FDA has approved Aimmune’s Palforzia for patients ages 4-17 with a confirmed peanut allergy. The drug … Continue reading “Aimmune Shares Explode on Peanut Allergy Treatment Approval from FDA”
